BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1443 related articles for article (PubMed ID: 26520780)

  • 21. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
    van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
    Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
    J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
    J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
    Wang Y; Pan L; Sheng XF; Chen S; Dai JZ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e23-9. PubMed ID: 24571331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
    Peters KB; Lou E; Desjardins A; Reardon DA; Lipp ES; Miller E; Herndon JE; McSherry F; Friedman HS; Vredenburgh JJ
    Oncologist; 2015 Jul; 20(7):727-8. PubMed ID: 26025933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
    Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.